Searchable abstracts of presentations at key conferences in endocrinology

ea0090p511 | Thyroid | ECE2023

Retrospective analysis of diagnostic and therapeutic management in thyroid cancer patients in 2019- 2021 to assess the possibility of treatment de-escalation

Kolton Magdalena , Handkiewicz-Junak Daria , Krajewska Jolanta

Introduction: In recent years, there has been a significant increase in the detection of thyroid cancer (TC) and a number of thyroid surgeries. Both the ATA 2015 and 2022 Polish guidelines allow sparing treatment in low-risk TC, nevertheless, most patients are qualified for total thyroidectomy.Material and method: The present study analyzed how often a TC patient opts for sparing treatment and the relationship between the size of the primary focus and ri...

ea0040l5 | Endocrine cancer: in the light of recent molecular studies | ESEBEC2016

Endocrine cancer: in the light of recent molecular studies

Jarza¸b Barbara , Krajewska Jolanta

Endocrine cancer constitutes a term and simultaneously a definition of a type of cancer, that is common in American literature whereas so far absent in European nomenclature. Detailed analysis of scientific programs of European endocrinological and oncological congresses proves that also these societies do not mention this type of cancer. To change this unfavorable situation a new clinical platform called European Task Group for Endocrine Cancer (ETEC), working under the auspi...

ea0063p1161 | Thyroid 3 | ECE2019

Do patients with differentiated thyroid cancer (DTC) harboring TERT promoter mutation require a more intensive treatment and follow-up? – proposal of a prospective study

Samborski Konrad , Krajewska Jolanta , Rusinek Dagmara , Oczko-Wojciechowska Magdalena , Jarzęb Barbara

Introduction: The importance of telomerase reverse transcriptase promoter (TERTp) mutations in DTC is widely discussed. It has been demonstrated that the presence of TERTp mutations is associated with higher cancer aggressiveness, reflected by lymph node metastases, distant metastases, advanced tumor stage, recurrence, and even disease-specific mortality. Nevertheless, there is no clear evidence-based data demonstrating how to manage these patients. Therefore...

ea0049ep1420 | Thyroid (non-cancer) | ECE2017

Prognostic value of preoperative serum calcitonin concentration on primary surgery outcomes in medullary thyroid cancer

Gawlik Tomasz , Kukulska Aleksandra , Wygoda Zbigniew , Krajewska Jolanta , Stobiecka Ewa , Czarniecka Agnieszka , Jarzab Barbara

Calcitonin assessment in thyroid diseases is recommended when medullary thyroid cancer (MTC) is suspected in fine needle biopsy, as well as in ‘suspicious for a follicular neoplasm’ class, especially oxyphilic type, in patients with germinal RET proto-oncogene mutation and in nondiagnostic biopsy when no surgical treatment is planned. This assessment is also suggested before any planned thyroid surgery to exclude MTC. Beyond diagnosis confirmation it is also suggeste...

ea0049ep1441 | Thyroid (non-cancer) | ECE2017

Cooperation between an endocrine nurse, psychologist and physician and their mediating role in the care of depression in patients treated with multi kinase inhibitors due thyroid cancer

Rozanska Alina , Syska-Bielak Anna , Kraus Justyna , Ocieczek Malgorzata , Wojtyna Ewa , Krajewska Jolanta

The treatment with multi kinase inhibitors (MKI) under clinical trials due to advanced thyroid cancer (TC) may postpone moving on the patients with advanced disease to the palliative care stage. However, chronic and escalating somatic symptoms during the treatment may promote the appearance of depressive reactions. It can be expected that a cognitive image of the disease, as a collection of subjective beliefs concerning patient’s own illness and treatment, will be an impo...

ea0092ps1-01-09 | Cancer | ETA2023

Risk of renal adverse effects in patients with advanced thyroid cancer who are undergoing radiological monitoring, with a particular focus on patients receiving tyrosine kinase inhibitors

Haras-Gil Malgorzata , Samborski Konrad , Ledwon Aleksandra , Kolton Magdalena , Handkiewicz-Junak Daria , Jarzab Barbara , Krajewska Jolanta

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

ea0035p562 | Endocrine tumours and neoplasia | ECE2014

Consolidation treatment with somatoatatin analogues after radiopeptide therapy

Sygula Aleksandra , Handkiewicz-Junak Daria , Kotecka-Blicharz Agnieszka , Hasse-Lazar Kornelia , Jurecka-Lubieniecka Beata , Krajewska Jolanta , Jarzab Barbara

Background: Although neuroendocrine tumours (NET) constitute a very heterogeneous group, most of them express somatostatin receptors that enable treatment with somatostatin analogues(SA), which proved to be effective both as bio- or radiopeptide therapy. However, little is now about combining this two treatment modalities.The aim of our prospective study was to evaluate results of radiolabeled somatostatin analogues (PRRT) with or without long lasting ‘cold’ SA as co...

ea0035p832 | Pituitary Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Correlation of coexpression of pituitary genes in QPCR and microarray study in pituitary adenomas

Zebracka-Gala Jadwiga , Larysz Dawid , Pfeifer Aleksandra , Rudnik Adam , Krajewska Jolanta , Hasse-Lazar Kornelia , Kowalska Malgorzata , Bazowski Piotr , Jarzab Barbara

Introduction: Mechanism of pathogenesis of pituitary adenomas is still unknown. Gene expression differences in pituitary cells of different origin are not extensively described. Identification of genes specific for pituitary adenomas should enable better understanding of differences in their response to therapy, especially to radiotherapy.Aim: The aim of our study was to evaluate the correlation of coexpression of distinct pituitary adenoma genes based o...

ea0020p239 | Bone/Calcium | ECE2009

The results of cinacalcet therapy in patients with severe or refractory hypercalcemia due to primary hyperparathyroidism

Krajewska Jolanta , Paliczka-Cieslik Ewa , Krawczyk Aleksandra , Szpak-Ulczok Sylwia , Michalik Barbara , Hasse-Lazar Kornelia , Jurecka-Lubieniecka Beata

Refractory or severe hypercalcemia is important clinical problem as it can lead to serious complications such as arrhythmias, acute or chronic pancreatitis, gastric ulcer, water and electrolyte balance disturbances, osteoporosis, psychoses and even to hypercalcemic crisis. Most often it is diagnosed in parathyroid cancer (PC). It is also observed in benign primary hyperparathyroidism (HPTH) in case of difficulties with adenoma’s localization. Routinely treatment includes ...